Investing.com reported that ENvue Medical stock slipped 1.5% in morning trading as the company's 1-for-12 reverse stock split became effective. ^[1] On 2026-08-27, JATT III Acquisition Corp closed its initial public offering of 6.9 million ordinary shares at $10 per share, including the underwriter's full overallotment of an additional 900,000 shares, generating $69 million in gross proceeds before underwriting discounts and offering expenses. ^[2] Every twelve pre-split shares were combined into one post-split share, reducing outstanding common shares from 11,084,616 to approximately 923,718. ^[3] Shares of ENvue Medical commenced post-split trading on the Nasdaq Capital Market under the existing ticker symbol FEED with a new CUSIP number. ^[4] The company announced the reverse split on August 28, 2026, with the ratio of 1-for-12 set to become effective on September 1, 2026. ^[5] AI Biotechnology LLC, an affiliate of Access Industries, Inc., and Vianti Capital Fund I, L.P. indicated non-binding interests to participate in a private placement that may occur concurrently with JATT III's initial business combination. ^[6] The JATT III offering included participation from Adage Capital Partners, L.P., ADAR1 Capital, Affinity Asset Advisors, LLC, Columbia Threadneedle Investments, Deep Track Capital, Great Point Partners, LLC, Janus Henderson Investors, Nantahala Capital, RA Capital Management, Sirenia Capital Management LP, Squadron Capital Management LLC, and other institutional investors. ^[7]